Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

ally fluctuate between periods of intense disease activity, during which the patient's own immune system is actively attacking and causing damage in their kidney, and periods of remission. Aspreva estimates that there are about 600,000 diagnosed lupus nephritis patients worldwide. There have been no new approved treatment options for SLE or lupus nephritis in the United States in over forty years. Current induction treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and immunosuppressants such as azathioprine. These treatments can also have life-threatening side effects that can be worse than the disease itself. Since the disease is more prevalent in women and tends to manifest itself when they are of child-bearing age, drugs that adversely affect fertility can also compound the negative impact of the disease on a patient's quality of life.

More About the Aspreva Lupus Nephritis Study

Aspreva's lupus nephritis study is one of the largest phase III studies ever conducted in lupus nephritis. This two-phase induction to maintenance study was designed as a randomized open label comparison of mycophenolate mofetil (MMF) with cyclophosphamide for the first six months (induction phase), followed by a double-blind comparison of MMF to azathioprine for up to three years (maintenance phase). Treatment response in the induction phase of this trial was defined as a decrease in proteinuria and the stabilization or improvement of serum creatinine. The first patient of this study was treated in July 2005 and patient enrollment was completed at the end of September, 2006. Re-randomization to the maintenance phase is complete and this phase of the study is ongoing. It is important to note that MMF is not currently approved by the FDA for the treatment of any autoimmune disease.

Conference Call

Aspreva will host a conference call to discuss results on Wednesday, June 27, 2007 at 9:30 a.m. ET (6:30 a.m. PT).


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/5/2009)...wswire/ -- ARKRAY, Inc., the world,s 5th largest m...oday announced that it has received 510(k) clearan...s new GLUCOCARD Vital blood glucose monitoring sys... ARKRAY will make available for distribution in ea...lement to the existing GLUCOCARD line of products,...
(Date:11/5/2009)...re/ -- DOTmed, the leading public medical equipmen...uipment auctions, today announced that they have b...Shared Services (MAGNET) to assist members in the ...ts. MAGNET was created to develop contracts on be...he market of capital equipment. ,, Derwood B. D...
(Date:11/5/2009)...-FirstCall/ -- Air Methods Corporation (Nasdaq: A...mber 30, 2009. Revenue increased 3% to $137.6 mil... For the nine-month period, revenue increased 3% t...ior-year nine-month period. The prior-year quarte...evenue generated from hurricane response activitie...
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2MAGNET Selects DOTmed.com to Assist Members in Sale of Used Medical Equipment and Idle Assets 2Air Methods Reports 3Q2009 Results and 4Q2009 Update 2Air Methods Reports 3Q2009 Results and 4Q2009 Update 3Air Methods Reports 3Q2009 Results and 4Q2009 Update 4Air Methods Reports 3Q2009 Results and 4Q2009 Update 5Air Methods Reports 3Q2009 Results and 4Q2009 Update 6Air Methods Reports 3Q2009 Results and 4Q2009 Update 7International Products Corp s Lab Offers Filter Membrane Compatibility and Studies 12770 1International Products Corp s Lab Offers Filter Membrane Compatibility and Studies 12770 2Researcher finds Girl Scout meetings provide an opportunity to increase girls physical activity 8990 1Researcher finds Girl Scout meetings provide an opportunity to increase girls physical activity 8990 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 1Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 4
...t and Phase 1b Combination Clinical Trials ...y, SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,...ata Saturday from two,clinical trials of the compa...595), including updated results of a Phase 1 trial...sed or refractory patients with acute,myeloid leuk...
...Pharmaceuticals,Inc. (Amex: ANX ) today provided ... Phase 2b clinical trial of CoFactor for the treat...verall survival results in this,study have been re...fluorouracil) arm demonstrating a 14 day improveme...5-FU arm., "In the Phase 2b study, CoFactor was d...
Other Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 2ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 3
(Date:11/5/2009)...ELES, Nov. 5 Justin Timberlake; Sa...Post were honored by the Cedars-Sinai Board of Gov... 4, 2009 at the Hyatt Regency Century Plaza in Los...us, benefitted the Cedar-Sinai Board of Governors ...n for the cause. ,, Justin Timberlake was ho...
(Date:11/5/2009)...as Important Implications for Genetic Testing and ...v. 5 Results of a lon...ent issue of Circulation play an important role in...g disease, according to the senior author, Micha...t at Mayo Clinic, Dr. Ackerman directs Mayo,s Long...
(Date:11/5/2009)...TE, N.C., Nov. 5 Southeast Anesthe...e at The Healthcare Leaders, Summit in Chile, Braz... ongoing, multi-year, continuing education event s...cal Devices & Diagnostic Group of the Johnson ...althcare quality and safety to Latin America to di...
(Date:11/5/2009)... Nov. 5 Kimberly-Clark C...ation of the waiting period under the Hart-Scott-R...ts previously announced planned acquisition of I-F...rk initiated a cash tender offer on October 20, 20...mmon stock. The tender offer will expire at midni...
(Date:11/5/2009)...URG, Ill., Nov. 5 Since...tive for the 2009 H1N1 influenza virus, pet owners...earn more: Can my pet get sick? What would the sym...w is it treated? ,, The American Veterinary Med...ct with experts and agencies across the country to...
Breaking Medicine News(10 mins):Health News:2009 Cedars-Sinai Board of Governors Gala Sponsored by Lexus Raises Over $2.6 Million 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 2Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 4
...s at $4 billion, similar to asthma , , MON...nited States, treatment of childhood constipation ...ma and attention-deficit hyperactivity disorder (A...8 who were diagnosed with constipation or prescrib...
...ockefeller Foundation, New York State Health Found...und, Prudential Social Investment Program and the ...ation Among Investors to Join Leading Advocate for... NEW YORK (Business Wire EON) December 8, 2008...
...Care and Associated Surgical & Medical Special... centers, announced today that they have entered i...ntly operate the surgery center in Franklin. , ...r patients," said James Barton, M.D., an otolaryng...
...ells from cell death and exerts resistance to chem...t can be exploited to target and kill the very tum... University of Illinois at Chicago show in a new s...cers. , "Akt is perhaps the most frequently acti...
...patients who have a poor relationship with their s...han would other women, according to a new study. ,...s in distressed marriages had higher levels of str...lity of the marital relationship may not be the fi...
... Toxic Air Pollution While EPA Shirks Responsibili...g USA TODAY released their study of schools where ...from chemical contamination to young children and ... (CHEJ) has been reporting since 2001. In several...
Other Medicine News:Health News:Childhood Constipation Carries a Big Price Tag 2Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 2Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 3Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 4Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 5Health News:Aurora and Associated Surgical & Medical Specialists Announce Surgery Center Joint Venture 2Health News:An Achilles heel in cancer cells 2Health News:Marital problems lead to poorer outcomes for breast cancer patients 2Health News:Marital problems lead to poorer outcomes for breast cancer patients 3Health News:If Your Child Says School Makes Him Sick - He Might Be Right 2
...nse Webster fixed curve catheters are available in...ing multi-electrode tip configurations and several...rafted to precise and demanding specifications, us...ulti-step process incorporating proven wire-braidi...
...nse Webster offers a wide range of fixed curve cat...eeds of children and other patients with small ana...specifications using only the finest materials. A ... wire braiding and extrusion technologies results ...
Inquiry Steerable Diagnostic Catheters
...d clinicians in performing Ankle/Brachial Index (A... complete packet of information. It includes a 10-... can be viewed on any computer with a CD drive. It... ABI test, provides information on the materials t...
Medicine Products: